A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Inclusion Criteria:

• Participants must be 55 to 90 years of age, inclusive, at the time of Screening (Visit 1).

• Participants must be diagnosed with Alzheimer's disease in accordance with the 2024revised criteria for diagnosis and staging of Alzheimer's Disease: Alzheimer'sAssociation Workgroup.

• Participants must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during orsubsequent to the onset of dementia to rule out other central nervous system (CNS)disease that could account for the dementia syndrome, eg, major stroke, neoplasm,subdural hematoma.

• Participants must have a history of psychotic symptoms (meeting InternationalPsychogeriatric Association criteria) for at least 2 months prior to Screening (Visit 1) (participants may or may not have symptoms of agitation).

Exclusion Criteria:

• Participants must not have psychotic symptoms that are primarily attributable to acondition other than the AD causing the dementia, eg, schizophrenia, schizoaffectivedisorder, delusional disorder, or mood disorder with psychotic features.

• Participants must not have history of major depressive episode with psychoticfeatures during the 12 months prior to Screening, or history of bipolar disorder,schizophrenia, or schizoaffective disorder.

• Participants must not have certain safety concerns, including certain laboratorytest irregularities.

• Other protocol-defined Inclusion/Exclusion criteria apply.